From aid to agency: the new economics of global cancer control
Amanda Stucke, lead of The Health Dividend initiative, reflects on a high-level roundtable discussion among 30 experts at London Global Cancer Week. The central question: how can countries finance cancer care as aid declines and costs climb—and why must the answer be economic, not charitable? The discussion offered a stark conclusion: the sector must reallocate, redesign, or else fall behind.
17 Dec 2025

Cancer care is racing into an era of scientific possibility, yet the financing to match is not keeping pace. That paradox animated a recent closed-door roundtable of global health leaders, industry figures, policymakers, philanthropists and researchers, convened during London Global Cancer Week. If hope was in the science, unease was in the spreadsheets.
Across low- and middle-income countries the picture is stark: households shoulder most of the costs, governments struggle to fill the gaps and donor support for non-communicable diseases has slipped. Even where national cancer plans exist, only a quarter come with real budgets attached to implement them—a quiet crisis of unfunded ambition. “Beautiful documents,” one participant said, “but broken hopes without financing.”
For a disease that will impact one in five people in their lifetime according to the World Health Organisation, this crisis is becoming louder. Behind every budget shortfall sits a delayed diagnosis, a broken machine or a family pushed into poverty. At several moments, frustration cut through the technical talk. “We cannot prevention-pilot our way out of a crisis that is already here,” one contributor warned, urging governments to confront the uncomfortable arithmetic of rising incidence and stagnant budgets.
A blunt question hung over the room: is the aid era over? Many thought so. With aid declining and political priorities shifting to defence, the old vision of disease-specific global funds no longer fits. The emerging consensus: the future of cancer financing is overwhelmingly domestic and augmented, not replaced, by catalytic and novel models of external support.
But domestic spending alone will not solve the problem unless it is spent differently. Around a fifth of global health spending is wasted—from misallocated budgets to idle equipment. Better-aligned incentives, stronger procurement and smarter use of technology—from AI-enabled imaging to tele-oncology—could unlock a “hidden funding source”.
Countries that have retooled their systems offer glimpses of what is possible. China has rapidly expanded social-health-insurance coverage while negotiating savings on innovative therapies. Several African countries are building domestic trust funds to reduce out-of-pocket payments. Local partnerships, from community-level prevention programmes to city-led cancer planning, show that reform often advances fastest outside central ministries.
Yet technological leapfrogging will falter if political leaders remain unconvinced. Ministers of finance, many agreed, are the real audience—not ministers of health. That requires a new narrative: cancer care not as a sunk cost but as an economic investment. Evidence is mounting. Early detection and prevention cut long-term costs. Multidisciplinary geriatric oncology reduces complications and hospitalisations. Countries that invest in resilient research ecosystems avoid dependence on external suppliers when crises hit. Health, in short, is an economic strategy.
What is missing is a forum to make that case convincingly. Several participants called for a regular platform—akin to those on climate and finance—that brings finance ministers, heads of government and global industry leaders together to examine the economic returns of cancer control.
This debate yielded several clear priorities for action:
Reframe the message: lead with economic value, not moral appeal.
Focus on political, not only technical, audiences: target heads of government; convene finance ministries.
Close the implementation gap: funded cancer plans, not aspirational ones.
Invest in early detection, prevention and workforce capacity: the highest-value, most neglected areas.
Build coalitions: public-private partnerships, blended finance and regional alliances can crowd in capital.
Strengthen accountability and data: no investment case stands without evidence of impact.
For The Health Dividend initiative, the message is clear: financing cancer care is an investment in prosperity—the core of our mission.